14th Annual Conference of the British HIV Association 23-25 April 2008, Belfast

TREATMENT EXPERIENCE WITH ETRAVIRINE AND OPTIMISED BACKGROUND REGIMEN: 24-WEEK DATA FROM A SINGLE CENTRE COHORT

HIV Med 2008 Apr 23-25 (Suppl 1);14:14 (abstract no. P18)

C Scott, R Jogiya, A Teague, M Bower, B Gazzard and M Nelson
Chelsea and Westminster Healthcare NHS Foundation Trust, London, UK

BACKGROUND: Etravirine (ETV) is a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) which demonstrates activity against both wild type HIV-1 and NNRTI resistant virus. We present week 24 responses in our patient cohort.

METHODS: Patients eligible for ETV expanded access program (EAP) were heavily pre-treated. Patients received ETV 200 mg bd plus OBR. OBR consisted of reverse transcriptase inhibitors ± protease inhibitors ± entry/fusion inhibitors ± integrase inhibitors. Baseline patient characteristics were analysed. CD4 cell count and viral load where measured at baseline, 12 and 24 weeks.

RESULTS:36 patients were enrolled into the EAP. 32/36 completed to week 24. 4 patients were lost to follow up. Median (range) baseline characteristics included CD4: 208 cells/mm³ (27-707), viral load: 7205 copies/mL (<50-500,000), drugs in OBR: 3 (1-4). 24/36 patients used daruvanir, 15/36 raltegravir, 1/36 maraviroc and 1/36 enfuvirtide in OBR. 10/36 patients used ETV with nucleoside analogues alone. The mean (range) of NNRTI resistance associated mutations in the cohort = 1 (0- 4). Mean (range) of ETV resistance associated mutations of patients in cohort = 1 (0-3). After 24 weeks therapy: median CD4 cell count increase and viral load decrease were 70 cell/mm³ and 2.37 log₁₀ copies/ mL respectively. 19/23 patients experienced >2log₁₀ decrease in viral load from baseline after 24 weeks. 27/36 (75%) patients had VL < 50 copies/mL at 24 weeks.

CONCLUSIONS: ETV is well tolerated and in combination with new novel anti-retroviral agents is a successful therapy in treatment experienced patients.

2008-04-23
P18

Copyright © 2008 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD